Cystatin E/M was originally identified as a cysteine protease inhibitor down-regulated in metastatic versus primary breast cancer cells [5,6], and subsequent studies have indicated that loss of cystatin E/M expression during the progression of breast cancer, glioma and lung cancer results from epigenetic silencing of the CST6 gene [7-11]. The gene discussed is CST6; the disease is lung cancer.